Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: SINTX Technologies, Inc. - SINTX Technologies, Inc. currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating a positive outlook for the stock [3][4] - The stock has shown significant price performance, with a 5.08% increase over the past week, contrasting with a 2.74% decline in the Zacks Medical - Instruments industry during the same period [6] - Over the past quarter, SINT's shares have risen by 56.36%, and by 44.78% over the last year, outperforming the S&P 500, which increased by 7.25% and 16.06% respectively [7] Trading Volume and Market Position - SINT's average 20-day trading volume is 106,104 shares, which serves as a baseline for price-to-volume analysis, indicating bullish or bearish trends [8] Earnings Outlook - In the last two months, one earnings estimate for SINT has increased, while none have decreased, leading to a consensus estimate improvement from -$3.44 to -$2.87 for the full year [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions, suggesting a positive earnings outlook [10] Conclusion - Considering the positive momentum indicators and earnings outlook, SINTX Technologies, Inc. is positioned as a promising investment opportunity with a Momentum Score of B and a Zacks Rank of 2 (Buy) [12]

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - The Zacks Momentum Style Score helps investors identify stocks with strong momentum, addressing the challenges of defining momentum [2] Company Overview: Lucid Diagnostics Inc. (LUCD) - Lucid Diagnostics Inc. currently holds a Momentum Style Score of B, indicating potential for solid momentum [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Performance Metrics - Over the past week, LUCD shares increased by 10.58%, while the Zacks Medical - Instruments industry declined by 2.74% [6] - In a longer timeframe, LUCD's monthly price change is 17.76%, significantly outperforming the industry's 0.67% [6] - Over the past quarter, LUCD shares rose by 12.5%, and over the last year, they gained 55.56%, compared to the S&P 500's increases of 7.25% and 16.06%, respectively [7] Trading Volume - LUCD's average 20-day trading volume is 1,341,620 shares, indicating a bullish sign with rising stock prices and above-average volume [8] Earnings Outlook - Recent earnings estimate revisions show one upward revision for the full year, raising the consensus estimate from -$0.41 to -$0.35 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive sentiment [10] Conclusion - Considering the performance metrics and earnings outlook, LUCD is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Core Insights - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] - Emcor Group (EME) currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating potential for outperformance [3][4] Company Performance - EME shares have increased by 1.43% over the past week, while the Zacks Building Products - Heavy Construction industry has decreased by 2.97% during the same period [6] - Over the last quarter, EME shares have risen by 20.39%, and over the past year, they have gained 54.41%, significantly outperforming the S&P 500, which increased by 7.25% and 16.06% respectively [7] - The average 20-day trading volume for EME is 964,360 shares, indicating a bullish trend when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for EME has increased, while none have decreased, raising the consensus estimate from $24.51 to $25.19 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions, suggesting a positive earnings outlook [10] Conclusion - Considering the positive momentum indicators and earnings outlook, EME is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" approach, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Fast-moving trending stocks can be difficult to enter at the right time, as they may lose momentum if future growth does not justify their high valuations [2] - A safer strategy involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Stock Analysis - a.k.a. Brands (AKA) - a.k.a. Brands has shown a price increase of 24.5% over the past four weeks, indicating growing investor interest [4] - The stock has gained 14.4% over the past 12 weeks, with a beta of 1.6, suggesting it moves 60% more than the market [5] - AKA has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] Group 3: Earnings and Valuation - An upward trend in earnings estimate revisions has led to a Zacks Rank 2 (Buy) for AKA, as analysts raising estimates attract more investor interest [7] - AKA is trading at a Price-to-Sales ratio of 0.23, meaning investors pay 23 cents for each dollar of sales, indicating a reasonable valuation [7] Group 4: Additional Opportunities - Besides AKA, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - Various Zacks Premium Screens are available to help identify winning stock picks based on different investing styles [9]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Triple Flag Precious Metals (TFPM) - TFPM currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance [3] Price Performance - TFPM shares have increased by 0.77% over the past week, while the Zacks Mining - Gold industry remained flat [5] - Over the last month, TFPM's price change is 11.98%, slightly below the industry's 12.5% [5] - In the past quarter, TFPM shares rose by 30.06%, and over the last year, they increased by 91.14%, significantly outperforming the S&P 500, which rose by 6.33% and 14.66% respectively [6] Trading Volume - TFPM's average 20-day trading volume is 721,671 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, 3 earnings estimates for TFPM have been revised upwards, while only 1 estimate was revised downwards, leading to an increase in the consensus estimate from $0.84 to $0.88 [9] - For the next fiscal year, 3 estimates have also moved upwards with no downward revisions [9] Conclusion - Given the strong momentum indicators and positive earnings outlook, TFPM is recommended as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [3] Performance Metrics - Over the past week, ALNY shares increased by 0.9%, while the Zacks Medical - Biomedical and Genetics industry declined by 0.34% [5] - In the last quarter, ALNY shares rose by 44.29%, and over the past year, they gained 63.33%, significantly outperforming the S&P 500, which increased by 6.33% and 14.66% respectively [6] - The average 20-day trading volume for ALNY is 1,102,099 shares, indicating a bullish trend when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for ALNY have been revised upwards, while none have been lowered, raising the consensus estimate from $3.35 to $3.98 [9] - For the next fiscal year, two estimates have increased, while one has decreased, reflecting a generally positive earnings outlook [9] Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a promising investment opportunity with a Momentum Score of A [11]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: First Majestic Silver (AG) - First Majestic Silver has a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Performance Metrics - Over the past week, AG shares increased by 9.33%, significantly outperforming the Zacks Mining - Silver industry, which rose by only 0.17% [5] - In a longer timeframe, AG's monthly price change is 33.17%, compared to the industry's 24.49% [5] - Over the last quarter, AG shares have risen by 56.04%, and over the past year, they have increased by 109.88%, while the S&P 500 only moved 6.33% and 14.66% respectively [6] Trading Volume - The average 20-day trading volume for AG is 25,988,994 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for AG have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.10 to $0.18 [9] - For the next fiscal year, two estimates have also moved upwards, indicating positive sentiment [9] Conclusion - Given the strong performance metrics and positive earnings outlook, AG is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a compelling option for investors seeking short-term gains [11]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Spruce Biosciences, Inc. (SPRB) - SPRB currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating a favorable outlook for the stock [2][3] - The stock has experienced significant price increases, with shares up 1868.25% over the past week, while the Zacks Medical - Biomedical and Genetics industry has seen a decline of 0.34% during the same period [5] - Over the last quarter, SPRB shares have risen 1860.75%, and are up 403.62% over the past year, significantly outperforming the S&P 500, which has moved 6.33% and 14.66% respectively [6] Trading Volume - SPRB's average 20-day trading volume is 1,450,847 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, one earnings estimate for SPRB has increased, while none have decreased, leading to a consensus estimate improvement from -$51.13 to -$2.83 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive sentiment [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, SPRB is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of buying low and waiting for recovery [1][2] Group 1: Momentum Investing Strategy - Momentum investors typically do not time the market, instead they capitalize on stocks that are already trending upwards [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if their valuations exceed future growth potential [2] Group 2: Commercial Metals (CMC) Stock Analysis - CMC has shown a price increase of 3.8% over the past four weeks, indicating growing investor interest [4] - Over the past 12 weeks, CMC's stock gained 12.5%, demonstrating its ability to deliver positive returns over a longer timeframe [5] - CMC has a beta of 1.32, suggesting it moves 32% more than the market in either direction, indicating fast-paced momentum [5] - CMC has a Momentum Score of A, suggesting it is an opportune time to invest in the stock [6] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investors [7] - CMC is trading at a Price-to-Sales ratio of 0.88, indicating it is reasonably valued at 88 cents for each dollar of sales [7] Group 3: Investment Opportunities - CMC is highlighted as a strong candidate for investment due to its favorable momentum characteristics and reasonable valuation [8] - There are additional stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Investors following momentum investing often avoid undervalued stocks, believing that quicker profits can be made from trending stocks [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] Group 2: Bargain Stocks with Momentum - Investing in bargain stocks that have recently shown price momentum may be a safer strategy [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Teladoc (TDOC) Analysis - Teladoc (TDOC) has shown a price increase of 13.5% over the past four weeks, indicating growing investor interest [3] - TDOC has gained 6.1% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.9, suggesting it moves 90% higher than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - TDOC has a Momentum Score of B, suggesting it is a favorable time to invest in the stock [5] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investors [6] - TDOC is trading at a Price-to-Sales ratio of 0.62, indicating it is relatively cheap, as investors pay only 62 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides TDOC, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [8]